View More Recent Stories

Apr 26, 2017 09:22AM Pre-Open Stock Movers 04/26: (AKBA) (IRTB) (TWTR) Higher; (X) (STX) (CREE) Lower (more...)
Apr 7, 2017 08:01AM AbbVie (ABBV), Neurocrine Biosciences (NBIX) Report Positive Phase 2b Data Showing Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids
Apr 7, 2017 08:00AM AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids
Feb 14, 2017 03:41PM JANA Partners Enters Aetna (AET), Bristol-Myers Squibb (BMY), Lamb Weston (LW), Salesforce (CRM) (more...) - 13F
Dec 1, 2016 10:00AM Neurocrine Biosciences (Nasdaq: NBIX) to Ring The Nasdaq Stock Market Opening Bell
Nov 14, 2016 07:49AM JANA Partners Enters Kate Spade (KATE), Select Medical (SEM), Twitter (TWTR) (more...)
Oct 19, 2016 09:02AM AbbVie (ABBV) and Neurocrine (NBIX) Announce Positive Pivotal Phase 3 Data for Elagolix in Premenopausal Women
Oct 19, 2016 09:00AM AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Menstrual Pelvic Pain Associated with Endometriosis at the American Society for
Oct 6, 2016 08:03AM AbbVie (ABBV) Announces Presentation of Data from Two Elagolix Phase 3s
Oct 6, 2016 08:00AM AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix and Research on the Economic Burden of Endometriosis at the 72nd American Society for Reproductive Medicine Scientific Congre
Feb 10, 2016 06:57AM AbbVie (ABBV) Announces Second Elagolix Phase 3 Met co-Primary Endpoints in Endometriosis (NBIX)
Feb 10, 2016 06:55AM AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
Jan 28, 2016 07:23AM AbbVie (ABBV), Neurocrine Bio (NBIX) Initiate Enrollment in Phase 3 Study of Elagolix in Patients with Uterine Fibroids
Jan 28, 2016 06:55AM AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
Sep 16, 2015 09:00AM AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids
Jun 16, 2015 03:28PM Notable 52-Week Highs and Lows 6/16: (CDK) (VDSI) (NBIX) High; (AAVL) (TWTR) (GG) Low
Jan 8, 2014 09:32AM Pre-Open Stock Movers 1/8: (PATH) (FRX) (MU) Higher; (TCS) (JCP) (TWTR) Lower (more...)
View More Recent Stories